Sugi Predict

Sugi Predict / Compounds / SCHEMBL1626644

SCHEMBL1626644

SCHEMBL1626644

O=C(O)c1cccc(C(F)(F)F)c1I

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TAS2R14 Q9NYV8 4/20 0.50
▸ FABP4 P15090 2/20 0.49
▸ LMNA P02545 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ ALDH1A1 P00352 3/20 0.45
▸ MEN1 O00255 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ DHODH Q02127 1/20 0.43
▸ HDAC6 Q9UBN7 1/20 0.43
▸ SLC6A9 P48067 2/20 0.43
▸ ALOX15 P16050 1/20 0.43
▸ KCNK3 O14649 1/20 0.42
▸ KCNK9 Q9NPC2 1/20 0.42
▸ HPGD P15428 2/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ ALB P02768 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ HDAC8 Q9BY41 1/20 0.41
▸ FABP3 P05413 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5802978 0.83 PARP1 (0.46) TAS2R14FABP4LMNAGAAALDH1A1
SCHEMBL31693044 0.83 LMNA (0.44) TAS2R14LMNAGAASLC6A9KCNK3
SCHEMBL1627534 0.83 LMNA (0.44) TAS2R14FABP4LMNAGAAALDH1A1
SCHEMBL28709149 0.81 ALOX15 (0.50) TAS2R14ALDH1A1ALOX15HPGDKDM4E
SCHEMBL221518 0.79 LMNA (0.62) TAS2R14FABP4LMNAGAAALDH1A1
SCHEMBL30449216 0.79 LMNA (0.62) TAS2R14FABP4LMNAGAAALDH1A1
SCHEMBL27273607 0.79 CFTR (0.51) TAS2R14LMNAGAAALDH1A1SLC6A9
SCHEMBL2443197 0.79 ALDH1A1 (0.60) ALDH1A1MEN1KMT2AALOX15HPGD
SCHEMBL2964734 0.78 TAS2R14 (0.51) TAS2R14FABP4LMNAGAAALDH1A1
SCHEMBL1195140 0.78 TAS2R14 (0.51) TAS2R14FABP4LMNAGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3856179-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-05-13 — — EP disclosed
US-20240327410-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2024-10-03 — — US disclosed
CN-113164458-B Monoacylglycerol lipase modulators 詹森药业有限公司 2024-09-13 — — CN disclosed
US-11993601-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV 2024-05-28 — — US disclosed
US-20230242531-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2023-08-03 — — US disclosed
US-11597728-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-03-07 — — US disclosed
US-20220315583-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2022-10-06 — — US disclosed
CN-113164458-A Monoacylglycerol lipase modulators 詹森药业有限公司 2021-07-23 — — CN disclosed
US-20200102311-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2020-04-02 — — US disclosed
EP-2231619-B1 INHIBITORS OF STEAROYL-COA DESATURASE HOFFMANN LA ROCHE (CH) 2014-11-26 — — EP disclosed
CN-101896473-A Inhibitors of stearoyl-coa desaturase HOFFMANN LA ROCHE 2010-11-24 — — CN disclosed
US-20100048572-A1 NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF AMGEN INC. (US) 2010-02-25 — — US disclosed
US-7652013-B2 Inhibitors of stearoyl-CoA desaturase HOFFMAN-LA ROCHE INC. (US) 2010-01-26 — — US disclosed
US-7635715-B2 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2009-12-22 — — US disclosed
EP-2111399-A2 NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF Amgen Inc. (US) 2009-10-28 — — EP disclosed
US-20090149466-A1 INHIBITORS OF STEAROYL-COA DESATURASE GILLESPIE PAUL 2009-06-11 — — US disclosed
US-20090093483-A1 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2009-04-09 — — US disclosed
WO-2008076427-A2 NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF AMGEN INC. (US) 2008-06-26 — — WO disclosed
US-20060211739-A1 Use of selective P2X7 receptor antagonists ABBOTT LABORATORIES 2006-09-21 — — US disclosed
WO-2006086229-A1 THE USE OF SELECTIVE P2X7 RECEPTOR ANTAGONISTS ABBOTT LABORATORIES (US) 2006-08-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048572-A1 NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF EGLN2, EGLN3, HIF1AN TAS2R14 4618/4885FABP4 1505/4885LMNA 1715/4885
US-20230242531-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP TAS2R14 2088/4885FABP4 234/4885LMNA 1845/4885
US-20090149466-A1 INHIBITORS OF STEAROYL-COA DESATURASE SCD, SCD5, FADS2 TAS2R14 3058/4885FABP4 6/4885LMNA 2327/4885
US-20090093483-A1 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof EGLN2, EGLN3, HIF1AN TAS2R14 4618/4885FABP4 1505/4885LMNA 1715/4885
US-20060211739-A1 Use of selective P2X7 receptor antagonists P2RX1, P2RX3, P2RX7 TAS2R14 1365/4885FABP4 4005/4885LMNA 3709/4885
US-11993601-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP TAS2R14 2088/4885FABP4 234/4885LMNA 1845/4885
US-20200102311-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP TAS2R14 2088/4885FABP4 234/4885LMNA 1845/4885
US-11597728-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP TAS2R14 2088/4885FABP4 234/4885LMNA 1845/4885
US-20240327410-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP TAS2R14 2088/4885FABP4 234/4885LMNA 1845/4885
US-20220315583-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP TAS2R14 2088/4885FABP4 234/4885LMNA 1845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.